Molecular Partners AG (CHIX:MOLNZ) FFO


CHIX:MOLNZ Molecular Partners AG CHIX:MOLNZ
35 GF Score
Price CHF3.21
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:MOLNZ
35GF Score
Molecular Partners AG CHIX:MOLNZ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (CHIX:MOLNZ) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.21 is trading 767.6% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for CHIX:MOLNZ:

  • FFO:
  • GF Value™: CHF0.37 vs. price of CHF3.21 (767.6% above fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the CHIX:MOLNZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
35GF Score

Get the complete analysis for CHIX:MOLNZ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.21
Price
CHF0.37
GF Value